A specialty pharmaceuticals distributor plays a role that is fundamentally different from a conventional pharmaceutical wholesaler. Specialty medicines include products used to treat complex, chronic, or life-threatening conditions that require special handling, precise documentation, and tightly managed supply chains. The margin for error is small, and the consequences of supply failure are often directly felt by patients.
Global use of specialty medicines is growing faster than any other pharmaceutical segment. According to the IQVIA Institute’s Global Medicine Use Trends 2026 report, pharmerging markets are expected to contribute approximately 121 billion dollars in additional pharmaceutical spending through 2030, with a significant portion concentrated in oncology, immunology, and rare disease categories. In oncology alone, novel modalities including cell and gene therapies, antibody-drug conjugates, and multispecific antibodies now account for 35 percent of all oncology clinical trials, reflecting the pace of innovation reaching patients.
For healthcare organisations in the Middle East, Central Asia, and Latin America, accessing specialty pharmaceuticals from Europe presents real operational challenges. Many of these products are not yet registered in destination markets, require specialist cold chain management, carry more complex documentation requirements, and are available through more limited supply channels. At the same time, for many patients, these medicines are the only available treatment option.
In this article, we explain what specialty pharmaceuticals are, which categories they cover, why their distribution from Europe involves distinct challenges, and what criteria matter most when selecting a reliable European specialty pharmaceutical distributor.
Table of Contents
- What Are Specialty Pharmaceuticals?
- Main Categories of Specialty Pharmaceuticals
- Why Specialty Pharmaceutical Distribution Is More Complex
- Specialty vs Standard Medicines: Comparison Table
- Cold Chain and Storage Requirements
- Documentation Requirements for Specialty Medicine Imports
- Accessing Specialty Pharmaceuticals in International Markets
- How to Select a Reliable European Specialty Pharmaceutical Distributor
- Conclusion
- Frequently Asked Questions
1. What Are Specialty Pharmaceuticals?
Specialty pharmaceuticals are medicinal products used to treat complex, chronic, or life-threatening conditions that require special conditions for storage, administration, or patient monitoring. Compared with standard medicines, they are typically more expensive, less widely available, and operate within narrower therapeutic windows where dosing and supply continuity have direct clinical significance.
The precise definition of a specialty medicine varies by country, but the category generally includes products with at least one of the following characteristics: they are biologically derived, require temperature-controlled storage, are indicated for rare or ultra-rare conditions, need specialist clinical monitoring, or are distributed through restricted access programmes.
What distinguishes specialty pharmaceuticals from a supply chain perspective is that small errors, whether a temperature deviation in transit, an incomplete documentation package at customs, or a delay in sourcing, can have direct and serious consequences for patients. This is what makes the choice of distribution partner in this segment more consequential than in conventional pharmaceutical procurement.
2. Main Categories of Specialty Pharmaceuticals
Specialty pharmaceuticals span a wide range of therapeutic areas. Understanding these categories helps procurement teams match their organisation’s specific needs with appropriate supply sources.
The main specialty pharmaceutical categories with significant international demand include:
- Oncology medicines: Targeted therapies, immunotherapies, antibody-drug conjugates, and cell and gene therapies. This category represents the largest share of specialty pharmaceutical spending and is growing at the fastest rate globally.
- Rare disease treatments: Products approved for conditions affecting fewer than five people per ten thousand population. This category typically carries the highest unit cost and the most restricted distribution channels. More than 90 percent of rare diseases currently have no biosimilar competition.
- Biologics and biosimilars: Medicines derived from living organisms, including monoclonal antibodies, recombinant proteins, and vaccines. All biologics require temperature-controlled supply chains.
- Immunology medicines: Biologic treatments for autoimmune conditions including rheumatoid arthritis, Crohn’s disease, psoriasis, and multiple sclerosis. Demand in GCC and Latin American markets is growing significantly.
- Specialty antivirals: Combination HIV regimens, hepatitis B and C treatments, and antiviral medicines for immunocompromised patients.
- Cell and gene therapies: The most complex category, including CAR-T cell therapies and gene therapies, requiring highly specialised distribution infrastructure and in some cases patient-specific logistics.
Each of these categories has distinct requirements for storage, transport, documentation, and regulatory compliance. These requirements should be understood in detail before beginning a procurement process.
3. Why Specialty Pharmaceutical Distribution Is More Complex
Distributing specialty pharmaceuticals from Europe involves a set of operational challenges that do not arise in standard pharmaceutical supply. Understanding these challenges before engaging a supplier helps procurement teams plan realistically and avoid delays with clinical consequences.
The main factors that make specialty pharmaceutical distribution more demanding include:
- Strict temperature requirements: Most specialty medicines, particularly biologics, must be stored and transported between 2 and 8 degrees Celsius. Some products require minus 20 or minus 80 degree storage. Even short temperature deviations can render a product completely unusable.
- Limited stock availability: Unlike high-volume generics, specialty medicines are often held in smaller quantities and sourced through fewer distribution channels. This directly affects lead times and the ability to respond quickly to urgent patient needs.
- Complex documentation: Beyond standard pharmaceutical documentation, specialty medicines often require temperature monitoring reports, validated packaging certification, orphan drug designation certificates, named patient import authorisation, and in some cases individual patient prescriptions.
- Destination-country registration status: Many specialty medicines are not registered in destination markets and can only be imported via special access pathways such as Named Patient Programmes or Compassionate Use frameworks.
- Manufacturer distribution restrictions: Many specialty pharmaceutical manufacturers operate controlled distribution networks. Not every European wholesaler can access every product.
Despite these complexities, for many patients in international markets there is no alternative to accessing these medicines. This is precisely what makes reliable specialty pharmaceutical distributors an essential component of international healthcare supply.
4. Specialty vs Standard Medicines: Comparison Table
For procurement teams new to specialty pharmaceutical sourcing, a side-by-side comparison with standard medicines helps clarify the key differences in supply chain requirements.
| Criteria | Specialty Medicines | Standard Medicines |
| Target condition | Complex, rare or life-threatening | More common and routine |
| Unit price | Significantly higher | Moderate to low |
| Temperature requirements | Often 2 to 8°C or frozen | Usually room temperature |
| Market availability | Limited | Generally broad |
| Distribution channels | Restricted and controlled | Broader access |
| Documentation complexity | Higher | Standard |
| Destination registration | Often complex | Usually simpler |
| Patient monitoring | Frequently mandatory | Usually optional |
| Generic alternative | Limited or none | Often available |
| Clinical experience | Shorter for newer products | Longer established |
What this comparison makes clear is that specialty pharmaceuticals require more attention at almost every stage of the supply chain. These additional requirements are precisely what makes choosing the right distribution partner a strategic decision.
5. Cold Chain and Storage Requirements
Cold chain management is one of the most critical and technically demanding aspects of specialty pharmaceutical distribution. Unlike standard medicines that can be stored at room temperature, biologics and many other specialty products can be permanently deactivated if exposed to incorrect temperatures, even briefly.
The core cold chain requirements for specialty pharmaceuticals include:
- Storage between 2 and 8 degrees Celsius for most biologics and protein-based medicines
- Minus 20 or minus 80 degree storage for specific products such as CAR-T cell therapies
- Continuous temperature monitoring throughout all stages from manufacturer warehouse to final delivery
- Use of validated, certified packaging for temperature-controlled shipments
- Complete temperature monitoring reports provided as part of the shipment documentation package
For international buyers, a specialty pharmaceutical distributor that cannot provide continuous temperature logs from the moment a product leaves the manufacturer’s warehouse to the point of delivery is not providing genuine cold chain assurance. A GDP certificate confirms that a system was approved at the time of assessment. It does not guarantee what is happening on each individual shipment. This distinction, in practice, is the difference between a product that arrives intact and one that does not.
6. Documentation Requirements for Specialty Medicine Imports
Documentation in specialty pharmaceutical imports carries even greater weight than in standard pharmaceutical procurement. These products often have very high unit value, are intended for specific patients, and in many cases represent the only available treatment. Any customs delay or import rejection has direct clinical consequences.
In addition to the standard documentation package covering CPP, CoA, GMP certificate, batch release records, and free sale certificate, specialty medicines frequently require additional documentation:
- Cold chain reports and continuous temperature logs from origin to destination
- Validated packaging certification for temperature-controlled shipments
- EMA Orphan Drug Designation certificate for rare disease medicines
- Named Patient Programme authorisation for products not registered in the destination country
- Compassionate Use framework documentation where applicable
- In some cases, prescribing physician documentation or hospital pharmacy committee approval
Destination-market requirements add further complexity. In GCC markets, Named Patient Import is one of the most common pathways for specialty oncology and rare disease medicines. Saudi Arabia’s SFDA, the UAE Health Authority, and Kuwait’s NHRA each have distinct procedures. In Central Asia, EU documentation forms a strong basis but local notarisation is typically required. In Brazil and Colombia, independent national registration systems apply with their own dossier format requirements.
7. Accessing Specialty Pharmaceuticals in International Markets
One of the real operational challenges for healthcare organisations in emerging markets is that many specialty pharmaceuticals are not formally registered in their country. This does not mean access is impossible, but it means the access pathway is more complex than standard import.
The main pathways used to access unregistered specialty pharmaceuticals include:
- Named Patient Programme: Import for a specific patient, based on a prescribing physician’s request and competent authority approval in the destination country. This is the most common pathway in GCC markets for oncology and rare disease medicines.
- Compassionate Use: Access to a medicine still in the regulatory approval process, for a patient with no other treatment option. Documentation requirements vary by country.
- Special Access Programme: Country-specific frameworks that permit import of specific medicines not yet registered nationally.
- Parallel import: In cases where the medicine is registered in one country in the region but not yet in the destination country.
Each of these pathways requires precise documentation and a distributor with genuine knowledge of local regulatory requirements. The difference between a distributor with real experience in these access routes and one without it can mean the difference between a patient receiving their medicine on time and waiting weeks longer than necessary.
8. How to Select a Reliable European Specialty Pharmaceutical Distributor
Selecting a specialty pharmaceutical distribution partner requires more careful evaluation than standard pharmaceutical procurement. In this segment, an unsuitable partner does not just create inconvenience. It can have direct clinical consequences for the patients who depend on these medicines.
The criteria that matter most when evaluating a European specialty pharmaceutical distributor include:
- Cold chain infrastructure: Does the distributor have GDP-certified storage with continuous temperature monitoring? Can they provide uninterrupted cold chain documentation from manufacturer to delivery?
- Category-specific experience: A distributor experienced in oncology supply is not necessarily the right partner for rare disease medicines or CAR-T therapies. Ask specifically about experience with the product category you need.
- Knowledge of special access pathways: Is the distributor familiar with Named Patient Programmes, Compassionate Use frameworks, and Special Access routes in your destination market?
- Qualified manufacturer relationships: Direct access to EMA-authorised manufacturers is essential for specialty pharmaceutical supply. Multi-tier intermediary chains increase risk and reduce traceability.
- Documentation support: The ability to assemble the full documentation package, including cold chain reports, orphan drug certificates, and special access authorisations, should be standard, not exceptional.
- Response time: In specialty pharmaceutical procurement, particularly for oncology and rare disease patients, how quickly a distributor responds to urgent requests has clinical significance.
Lenus Health operates as a pharmaceutical wholesaler and specialty medicine distributor based in Germany. We work with qualified manufacturers across the EU and provide complete documentation for every specialty pharmaceutical shipment. Our team has direct experience with the regulatory requirements of Middle Eastern, Central Asian, and Latin American markets for specialty medicine access.
9. Conclusion
Specialty pharmaceutical distribution from Europe is one of the most technically and operationally demanding areas of international pharmaceutical supply. From oncology and rare diseases to biologics and cell therapies, these medicines carry requirements for cold chain management, documentation, regulatory access pathways, and supply chain oversight that do not exist in standard pharmaceutical procurement.
For healthcare organisations in international markets that need access to these medicines, two things matter most: choosing a distributor with the technical infrastructure, clinical knowledge, and regulatory expertise to handle specialty supply reliably; and understanding the access pathways available when a medicine is not yet registered in the destination country.
In a segment where innovation is moving faster than registration timelines, and where the patients who need these medicines often have no alternatives, supply reliability is not a commercial consideration. It is a clinical one. If your organisation requires specialty pharmaceuticals sourced from Europe, we welcome the opportunity to discuss your requirements.
10. Frequently Asked Questions
- What are specialty pharmaceuticals?
Specialty pharmaceuticals are medicines used to treat complex, chronic, or life-threatening conditions that require special conditions for storage, administration, or patient monitoring. They are typically more expensive than standard medicines, available through more limited supply channels, and often require cold chain management. For many patients in categories such as oncology or rare disease, specialty medicines represent the only available treatment option. - Why are many specialty pharmaceuticals not registered in international markets?
Pharmaceutical product registration requires significant time and resources in each country. Manufacturers typically prioritise registration in markets based on volume and commercial viability. Smaller markets or those with more complex registration processes may be included in later phases of a registration programme. In the meantime, pathways such as Named Patient Programmes and Compassionate Use frameworks allow legal access to unregistered specialty medicines. - What is a Named Patient Programme?
A Named Patient Programme is a special access pathway that allows physicians to request import of medicines not yet registered in their country for specific, identified patients. The process requires a prescribing physician’s documentation, competent authority approval in the destination country, and specific import documentation from the supplying country. In GCC markets, Named Patient Import is one of the most commonly used pathways for specialty oncology and rare disease medicines. - How important is cold chain management for specialty pharmaceuticals?
Cold chain integrity is one of the most critical factors in specialty pharmaceutical supply. Biologics and many other specialty medicines can be permanently deactivated by temperature deviations, even brief ones. A qualified distributor must be able to provide continuous temperature monitoring reports from the manufacturer’s warehouse to the point of delivery. A GDP certificate confirms that a distributor’s system was approved at assessment. It does not guarantee what happens on each shipment. The temperature log is the evidence of what actually occurred. - What documentation is required for specialty medicine imports?
In addition to standard pharmaceutical documentation including CPP, CoA, GMP certificate, and batch release records, specialty medicines frequently require cold chain monitoring reports, validated packaging certification, EMA Orphan Drug Designation certificates for rare disease products, and Named Patient Programme or Compassionate Use authorisation for products not registered in the destination country. Requirements vary by product type and destination market. - Can specialty pharmaceuticals be exported to countries where they are not registered?
Yes, via special access pathways rather than standard commercial import. The most common routes are Named Patient Programmes, Compassionate Use frameworks, and Special Access Programmes. Each has its own documentation requirements and requires familiarity with the regulatory process in the destination country. An experienced specialty pharmaceutical distributor can identify the most appropriate access pathway for each product and market.
